The details of the LOXO-101 oral presentation is as follows: Press Program Date & Time: November 8, 2015, 10:30 a.m. Eastern Time Oral Presentation Date & Time: November 8, 2015, 3:45 p.m. to 4:25 p.m. Eastern Time Title: Clinical Safety and Activity from a Phase 1 Study of LOXO-101, a Selective TRKA/B/C Inhibitor, in Solid Tumor Patients with NTRK Gene Fusions Session: Spotlight on Proffered Papers Session 3 Presenter: David Hong, M.D., deputy chair, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Location: Veteran's Memorial AuditoriumThe details of the Loxo Oncology poster presentations are as follows: Poster Session Data & Time: November 7, 2015, 12:30 p.m. to 3:30 p.m. Eastern Time Title: Identification and Characterization of Highly Potent and Selective Kinase Inhibitors for the Treatment of RET-Driven Cancers Session: Poster Session B, Therapeutic Agents: Small Molecule Kinase Inhibitors Abstract Number: B192 Location: Exhibit Hall C-D Poster Session Date & Time: November 8, 2015, 12:30 p.m. to 3:30 p.m. Eastern Time Title: Identification of First-in-Class, Highly Potent FGFR Kinase Inhibitors that Spare FGFR1 Session: Poster Session C, Therapeutic Agents: Small Molecule Kinase Inhibitors Abstract Number: C196 Location: Exhibit Hall C-D Conference Call and Webcast Information Loxo Oncology will host a conference call, live webcast with slides and Q&A on Monday, November 9, 2015 at 8:00 a.m. Eastern Time to discuss the LOXO-101 data and pipeline program updates. To participate in the conference call, please dial (877) 930-8065 (domestic) or (253) 336-8041 (international) and refer to conference ID 66690460. A live webcast of the presentation will be available at http://ir.loxooncology.com/. A replay of the webcast will be available shortly after the conclusion of the call and archived on the company's website for 30 days following the call. About LOXO-101 LOXO-101 is a potent, oral and selective investigational new drug in clinical development for the treatment of patients with cancers that harbor abnormalities involving the tropomyosin receptor kinases (TRKs). Growing research suggests that the NTRK genes, which encode for TRKs, can become abnormally fused to other genes, resulting in growth signals that can lead to cancer in many sites of the body. In an ongoing Phase 1 clinical trial, LOXO-101 has demonstrated encouraging preliminary efficacy. LOXO-101 is also being evaluated in a global Phase 2 multi-center basket trial in patients with solid tumors that harbor TRK gene fusions. For additional information about both the LOXO-101 clinical trials, please refer to www.clinicaltrials.gov. Interested patients and physicians can contact the Loxo Oncology Physician and Patient Clinical Trial Hotline at 1-855-NTRK-123. About Loxo Oncology Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com. Forward Looking Statements This press release contains "forward-looking" statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our partnerships, timing and success of our clinical trials, the potential therapeutic benefits and economic value of our lead product candidate, potential growth opportunities and potential market opportunities. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Quarterly Report on Form 10-Q, and other reports as filed from time to time with the Securities and Exchange Commission. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Contacts for Loxo Oncology, Inc.Company:Jacob S. Van NaardenVice President, Corporate Development and Strategyjake@loxooncology.comInvestors:Peter Rahmer The Trout Group, LLC 646-378-2973 email@example.com Media:Dan Budwick Pure Communications, Inc. 973-271-6085 firstname.lastname@example.org